Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). PDL BioPharma's share price for the quarter that ended in Jun. 2020 was $2.69331. PDL BioPharma's Shares Outstanding (EOP) for the quarter that ended in Jun. 2020 was 113.95 Mil. Therefore, PDL BioPharma's market cap for the quarter that ended in Jun. 2020 was $306.89 Mil.
PDL BioPharma's quarterly market cap
declined
from Dec. 2019 ($309.51 Mil) to Mar. 2020 ($259.46 Mil) but then
increased
from Mar. 2020 ($259.46 Mil) to Jun. 2020 ($306.89 Mil).
PDL BioPharma's annual market cap
declined
from Dec. 2017 ($324.47 Mil) to Dec. 2018 ($304.42 Mil) but then
increased
from Dec. 2018 ($304.42 Mil) to Dec. 2019 ($309.51 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. PDL BioPharma's Enterprise Value for Today is $282.14 Mil.
PDL BioPharma Market Cap Historical Data
The historical data trend for PDL BioPharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of PDL BioPharma's Market Cap
For the Biotechnology subindustry, PDL BioPharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PDL BioPharma's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PDL BioPharma's Market Cap distribution charts can be found below:
* The bar in red indicates where PDL BioPharma's Market Cap falls into.
PDL BioPharma Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
PDL BioPharma's Market Cap for the fiscal year that ended in Dec. 2019 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PDL BioPharma (NAS:PDLI) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
PDL BioPharma Market Cap Related Terms
Thank you for viewing the detailed overview of PDL BioPharma's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
PDL BioPharma (PDL BioPharma) Business Description
PDL BioPharma Inc acquires and manages a portfolio of companies, products, royalty agreements and debt facilities in the biotech, pharmaceutical and medical device industries. The operating segments of the company are Medical Devices, Strategic Positions, Pharmaceutical and Income Generating Assets, of which key revenue is derived from the Pharmaceutical segment. The Pharmaceutical segment consists of revenue derived from branded prescription medicine products sold under the name Tekturna and Tekturna HCT in the U.S, and Rasilez and Rasilez HCT in the rest of the world (collectively, the Noden Products). Geographically, the company operates in Europe, North America, Asia and Other countries, of which prime revenue is generated from Asia and North America.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PDLI has been successfully added to your 